Furthermore, curcumin-like denosumab, a monoclonal antibody for the treatment of osteoporosis, suppresses RANKL by inhibiting IKK and NF-KB activation or acts as a ROS scavenger to protect against bone destruction, decrease tumor burden, and also improve survival of osteosarcoma patients after chemotherapy [30]. The gene discussed is TNFSF11; the disease is osteosarcoma.